IGHE and asthma: Initially, the availability of omalizumab changed the treatment of asthma related to IgE-mediated allergic pathogenesis, and more recently, the availability of drugs targeting IL-5, which is a fundamental factor in the differentiation, activation and survival of eosinophils, changed the treatment strategy for the eosinophilic phenotype [22].